glp-1 compound podcast New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Podcast: The Truth About GLP-1s

The insatiable demand saw Mounjaro or tirzepatide arrive at the end of 2023 and now a newer, reportedly more effective drug called retatrutide is in the pipeline

You can log shots or pills, track weight, record meals, monitor water intake, and see your progress over time

We searched PubMed, Web of Science, and Embase from inception through April 2025 using the terms GLP-1 receptor agonists, GLP-1RAs, neurodegeneration, Alzheimer's, Parkinson's, multiple sclerosis, ALS, mechanisms, clinical trials, and biomarkers. Studies were included if they were English-language, peer-reviewed, and focused on central nervous system effects

Manufacturers who build health economic evidence and outcomes-based contracting capabilities now will be commercially advantaged when that change takes effect

These agents mimic the action of glucagon-like peptide-1, stimulating insulin secretion, slowing gastric emptying, and promoting satiety

The three most common active ingredients used in GLP-1s are semaglutide, liraglutide, and tirzepatide